BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, May 5, 2026
Home » Authors » Catherine Shaffer

Catherine Shaffer

Articles

ARTICLES

NovImmune Tops Off Licensing Deal with $20.6 M

Dec. 20, 2010
By Catherine Shaffer
An earlier lucrative licensing deal with Genentech Inc. helped Swiss biotech NovImmune SA to secure an additional $20.6 million Series B financing. The Genentech deal for rights to NovImmune's anti-Interleukin-17 (IL-17) antibody program, finalized in July, provided enough external validation to draw the interest of lead investor BZ Bank Aktiengesellschaft. The funds will be used to develop proof-of-concept data on two of NovImmune's compounds and complete validation of its antibody platform.
Read More

Cypress Relents on New Offer from Ramius, Royalty Pharma

Dec. 16, 2010
By Catherine Shaffer
Ramius V&O Acquisition LLC and Royalty Pharma, of New York, will acquire Cypress Bioscience Inc., of San Diego, in an all-cash transaction worth approximately $255 million.
Read More

OPKO Flips Nausea Drug Rolapitant to Tesaro for $121M

Dec. 15, 2010
By Catherine Shaffer
Tesaro Inc. has acquired rights to nausea drug rolapitant and one other drug from OPKO Health Inc. for $121 million Including milestones, double-digit, tiered royalties and a 10 percent equity position in Tesaro. Rolapitant was a Schering-Plough Corp. property, but OPKO nabbed it for just $2 million up front following Schering's 2009 merger with Merck and Co. Inc.
Read More

At-the-Market Financing Facility Secures ISCO $25M

Dec. 14, 2010
By Catherine Shaffer
Aspire Capital Fund LLC agreed to purchase 333,333 shares of International Stem Cell Corp. (ISCO) at $1.50 per share, a 7 percent premium over Friday's closing price of $1.40. In addition, the agreement includes a financing facility that will allow Aspire to purchase up to a total of $25 million in equity capital over the next three years, at the discretion of ISCO.
Read More

MIPI Files for Chapter 11, and Gets $45M Financing

Dec. 13, 2010
By Catherine Shaffer
Molecular Insight Pharmaceuticals Inc. will undergo a corporate reorganization under a Chapter 11 filing pursuant to a $45 million financing commitment from Savitr Capital LLC.
Read More

NewCo News: Ligon Turns Microarray Screening Upside Down

Dec. 9, 2010
By Catherine Shaffer
Some potential protein drug targets, such as transcription factors, are difficult to study well in a high-density screening situation. Many transcription factors flop around like wet noodles with little organized structure, and are regarded as "undruggable" by many pharma companies.
Read More

Cephalon Bets on Stem Cells with $350M Mesoblast Deal

Dec. 9, 2010
By Catherine Shaffer
Cephalon Inc. is betting that its short-term $350 million investment in stem cell technology will help to plug a much more expensive hole with the April 2012 patent expiration of its sleep disorder drug Provigil.
Read More

Brentuximab Shines in ALCL, Blows Away the Endpoints

Dec. 8, 2010
By Catherine Shaffer

Thrombogenics Builds War Chest with $75M Placement

Dec. 6, 2010
By Catherine Shaffer

Alnylam CEO: Big Pharma Still Confident in Potential of RNAi

Nov. 29, 2010
By Catherine Shaffer
View All Articles by Catherine Shaffer

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 4, 2026.
  • University of Western Australia patents 5-HT2A/B modulators

    BioWorld Science
    University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
  • EQ-504 is AhR agonist for ulcerative colitis, related disorders

    BioWorld Science
    Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has...
  • Alceptor Therapeutics discovers new α2B-adrenoceptor agonists

    BioWorld Science
    Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
  • Glucagon-like peptide-1 receptor (GLP-1R) complex

    Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control

    BioWorld
    A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing